Neurosterix has raised $105 million in Series B financing to advance its lead schizophrenia treatment into Phase 2 development and expand its pipeline of selective allosteric modulators for neuropsychiatric disorders.
RTW Investments led the round. New investors Janus Henderson Investors, GV, Ikarian Capital, Affinity Asset Advisors, and Dellora Investments participated alongside existing backers Perceptive Advisors and Acorn Bioventures.
The company’s lead candidate, NTX-253, is an oral, brain-penetrant positive allosteric modulator designed to regulate the muscarinic M4 receptor. The target has been clinically validated as an alternative to traditional schizophrenia medicines that act through dopamine pathways.
Neurosterix completed Phase 1 single- and multiple-ascending-dose studies of NTX-253. The pharmacokinetic results supported once-daily oral dosing and further clinical evaluation as a potentially differentiated antipsychotic treatment.
The company is also developing NTX-819, a potential first-in-class negative allosteric modulator of metabotropic glutamate receptor 7 for mood, stress, and aggression-related conditions. NTX-529 is a second M4 program intended for additional psychosis and mood disorders.
Neurosterix has more than 100 patent filings, a proprietary library exceeding 80,000 compounds, and over 200 functional assays relevant to central nervous system drug discovery.
The company also appointed Karuna Therapeutics founder Andrew Miller as executive chair, former Pfizer executive Edmund Harrigan as an independent director, and former Karuna Chief Medical Officer Stephen Brannan as chair of its Clinical Advisory Board.
Miller and Brannan helped develop the first approved muscarinic-based schizophrenia therapy. Their appointments add experience in clinical development, regulation, company building, and commercialization as Neurosterix prepares NTX-253 for its next trial.
KEY QUOTES
“We believe Neurosterix is entering a defining stage in its development with NTX-253, our selective M4 allosteric modulator, as we prepare to enter Phase 2 clinical development.”
Fred Callori, Chief Executive Officer of Neurosterix
“I believe Neurosterix’s highly selective approach to M4 modulation has the opportunity to be an important next generation muscarinic treatment building on promising early clinical findings.”
Andrew Miller, PhD, Executive Chair of Neurosterix

